跳至主要内容
临床试验/DRKS00029563
DRKS00029563已完成未知

Investigation of the effects of cartilage structure nutrients on symptoms of knee osteoarthritis: a 12-weeks, randomized, double-blind, placebo-controlled pilot study - BTS1834/22

Apomedica Pharmazeutische Produkte GmbH0 个研究点目标入组 54 人开始时间: 2022年7月12日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
54

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
40 Years 至 75 Years(—)
性别
All

入选标准

  • Main inclusion criteria:
  • Subject is able and willing to sign the Informed Consent Form prior to screening evaluations
  • Sex: female and male (minimum 25% of each gender)
  • Subjects with primary osteoarthritis who are not expected to require surgical treatment for at least three months after inclusion.
  • Known X-ray or MRI finding (Kellgren score of 1 to 3; X-ray or MRI not older than 36 months)
  • Discomfort over a period of at least 3 months
  • KOOS pain score with maximum 75 (Maximum 100 (no pain problems)) at screening
  • Age: 40 – 75 years
  • BMI: 19 – 32 kg/m2
  • Subjects agree to maintain physical activity levels throughout the study
  • Except for osteoarthritis, the subject is in good physical and mental health as established by medical history, physical examination, vital signs, results of biochemistry, hematology

排除标准

  • Main exclusion criteria
  • Inflammatory, infectious or metabolic joint disorder
  • Artificial joint replacement in knees or hip
  • Surgery within the last 6 months in knees or hip
  • Intra-articular therapy within the last 3 months
  • Oral cartilage treatment within the last 3 months including also supplements e.g. glucosamine, chondroitin, hyaluronic acid or collagen.
  • Medical treatment of joint disease besides Paracetamol as analgesic medication for emergency treatment
  • Relevant history or presence of any severe medical disorder, potentially interfering with this study (e.g. mal absorption, chronic gastro-intestinal diseases (e.g. Morbus Crohn, Colitis Ulcerosa), heavy depression, significant cardiovascular disease or co-morbidities (e.g. myocardial infarction, stroke, congestive heart failure), diabetes, acute malignant disease within last 3 years except basal cell carcinoma of the skin, etc.)
  • Present or recent use of drugs and dietary supplements with anti-inflammatory properties that could interfere with the study 2 months before or during the study (e.g. Curcumin, omega-3 FA, chronic intake of NSAR, ibuprofen, glucocorticoids (except inhalative) etc.), antioxidative supplements (e.g. vitamin C, vitamin E) or further antioxidative supplements (e.g. OPC etc.).

研究者

相似试验